Pharming (PHAR) Equity Income (2020 - 2025)
Historic Equity Income for Pharming (PHAR) over the last 7 years, with Q3 2025 value amounting to -$37000.0.
- Pharming's Equity Income rose 9162.9% to -$37000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.0 million, marking a year-over-year decrease of 37152.78%. This contributed to the annual value of -$1.8 million for FY2024, which is 50899.65% down from last year.
- Per Pharming's latest filing, its Equity Income stood at -$37000.0 for Q3 2025, which was up 9162.9% from $8000.0 recorded in Q2 2025.
- Over the past 5 years, Pharming's Equity Income peaked at $834000.0 during Q2 2024, and registered a low of -$1.8 million during Q4 2024.
- In the last 5 years, Pharming's Equity Income had a median value of -$100000.0 in 2022 and averaged -$172764.9.
- Per our database at Business Quant, Pharming's Equity Income skyrocketed by 63780.49% in 2022 and then crashed by 53027.52% in 2023.
- Over the past 5 years, Pharming's Equity Income (Quarter) stood at -$82000.0 in 2021, then plummeted by 387.8% to -$400000.0 in 2022, then increased by 27.75% to -$289000.0 in 2023, then plummeted by 508.3% to -$1.8 million in 2024, then surged by 97.9% to -$37000.0 in 2025.
- Its Equity Income was -$37000.0 in Q3 2025, compared to $8000.0 in Q2 2025 and -$250000.0 in Q1 2025.